Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities

doi:10.3748/wjg.v27.i39.6527

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 39

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7111)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

487

WORD

131

HTML

4698

Tables (1-3)

646

Sum=5962

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

495

Download

654

Sum=1149

Oct 21, 2021 (publication date) through Feb 24, 2025

Times Cited of This Article

Times Cited (32)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Oct 21, 2021; 27(39): 6527-6550
Published online Oct 21, 2021. doi: 10.3748/wjg.v27.i39.6527

Table 2 Pancreatic ductal adenocarcinoma trials involving agents that target tumor metabolism

Drug	Target	Trial description	NCI trial number
IACS-010759	OXPHOS inhibitor	Phase I, in advanced cancers	NCT03291938
CPI-613	PDH/alpha KDH inhibitor	Phase I, combination with Gem + nab-paclitaxel	NCT03435289
CPI-613	PDH/alpha KDH inhibitor	Phase II, combination with FOLFIRINOX	NCT03699319
CPI-613	PDH/alpha KDH inhibitor	Phase III, combination with modified FOLFIRINOX	NCT03504423
Metformin and atorvastatin	Metabolic inhibitors	Metformin + Atorvastatin + Doxycycline + Mebendazole in cancers	NCT02201381
L-glutamine	Glutamine analog	Phase I, combination with Gem + nab-paclitaxel	NCT04634539

OXPHOS: Oxidative phosphorylation; PDH: Pyruvate dehydrogenase; KDH: Ketoglutarate dehydrogenase.

Citation: Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World J Gastroenterol 2021; 27(39): 6527-6550
URL: https://www.wjgnet.com/1007-9327/full/v27/i39/6527.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i39.6527